About Ariad Pharmaceuticals (NASDAQ:ARIA)
ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:ARIA
- CUSIP: 04033A10
- Web: www.ariad.com
Average Prices:- 50 Day Moving Avg: $21.86
- 200 Day Moving Avg: $14.14
- 52 Week Range: $4.67 - $23.99
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -57.12
- P/E Growth: 0.00
Profitability:- Net Margins: -60.47%
- Return on Assets: -17.16%
Debt:- Debt-to-Equity Ratio: -11.28%
- Current Ratio: 3.17%
- Quick Ratio: 3.15%
Misc:- Average Volume: 9.91 million shs.
- Beta: 2.16
Frequently Asked Questions for Ariad Pharmaceuticals (NASDAQ:ARIA)
What is Ariad Pharmaceuticals' stock symbol?
Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."
How were Ariad Pharmaceuticals' earnings last quarter?
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) released its earnings results on Thursday, July, 28th. The company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.11) by $0.70. The company earned $65.30 million during the quarter, compared to the consensus estimate of $60.64 million. The firm's quarterly revenue was up 133.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.28) EPS. View Ariad Pharmaceuticals' Earnings History.
Where is Ariad Pharmaceuticals' stock going? Where will Ariad Pharmaceuticals' stock price be in 2017?
9 equities research analysts have issued twelve-month price objectives for Ariad Pharmaceuticals' shares. Their predictions range from $7.00 to $24.00. On average, they expect Ariad Pharmaceuticals' share price to reach $16.11 in the next twelve months. View Analyst Ratings for Ariad Pharmaceuticals.
Who are some of Ariad Pharmaceuticals' key competitors?
Some companies that are related to Ariad Pharmaceuticals include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Kite Pharma (KITE), Exelixis (EXEL), TESARO (TSRO), BIOVERATIV INC (BIVV), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), Juno Therapeutics (JUNO), Clovis Oncology (CLVS), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), Spark Therapeutics (ONCE), GW Pharmaceuticals PLC (GWPH) and Halozyme Therapeutics (HALO).
How do I buy Ariad Pharmaceuticals stock?
Shares of Ariad Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ariad Pharmaceuticals' stock price today?
One share of Ariad Pharmaceuticals stock can currently be purchased for approximately $23.99.
MarketBeat Community Rating for Ariad Pharmaceuticals (NASDAQ ARIA)MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 6 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.11) |
| Consensus Price Target: | $16.11 (32.85% downside) |
Consensus Price Target History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 1/11/2017 | SunTrust Banks, Inc. | Downgrade | Buy -> Hold | $24.00 | N/A |  |
| 1/10/2017 | Cowen and Company | Reiterated Rating | Buy | $16.00 | N/A | |
| 1/10/2017 | Leerink Swann | Downgrade | Outperform -> Market Perform | | N/A | |
| 1/10/2017 | Barclays PLC | Upgrade | Underweight -> Equal Weight | $9.00 -> $24.00 | N/A | |
| 1/10/2017 | Jefferies Group LLC | Downgrade | Buy -> Hold | $11.00 -> $24.00 | N/A | |
| 12/10/2016 | William Blair | Reiterated Rating | Outperform | $15.00 | N/A | |
| 12/1/2016 | JMP Securities | Reiterated Rating | Market Perform | | N/A | |
| 11/3/2016 | Deutsche Bank AG | Initiated Coverage | Hold | $9.50 | N/A | |
| 10/24/2016 | J P Morgan Chase & Co | Downgrade | Neutral -> Underweight | $9.97 -> $7.00 | N/A | |
| 6/20/2016 | Royal Bank Of Canada | Reiterated Rating | Hold | | N/A | |
| 2/22/2016 | Goldman Sachs Group, Inc. (The) | Lower Price Target | | $7.00 -> $5.00 | N/A | |
(Data available from 10/17/2015 forward)
Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)Earnings History by Quarter for Ariad Pharmaceuticals (NASDAQ ARIA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2016 | Q316 | ($0.19) | ($0.14) | $42.93 million | $34.30 million | View | Listen | |
| 7/28/2016 | Q216 | ($0.11) | $0.59 | $60.64 million | $65.30 million | View | Listen | |
| 5/10/2016 | Q116 | ($0.27) | ($0.23) | $43.06 million | $35.60 million | View | Listen | |
| 2/23/2016 | Q415 | ($0.32) | ($0.32) | $44.79 million | $36.50 million | View | Listen | |
| 11/3/2015 | Q315 | ($0.23) | ($0.29) | $46.09 million | $27.50 million | View | Listen | |
| 8/5/2015 | Q215 | ($0.27) | ($0.33) | $33.24 million | $27.80 million | View | Listen | |
| 5/7/2015 | Q115 | ($0.27) | ($0.28) | $27.26 million | $23.90 million | View | Listen | |
| 2/19/2015 | Q414 | ($0.12) | ($0.03) | $39.50 million | $66.00 million | View | Listen | |
| 11/5/2014 | Q314 | ($0.30) | ($0.27) | $16.50 million | $14.70 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.27) | ($0.30) | $13.65 million | $12.10 million | View | Listen | |
| 5/7/2014 | Q114 | ($0.32) | ($0.27) | $10.41 million | $11.80 million | View | Listen | |
| 2/25/2014 | Q413 | ($0.47) | ($0.40) | $6.31 million | $8.28 million | View | Listen | |
| 11/6/2013 | Q313 | ($0.43) | ($0.36) | $16.67 million | $16.70 million | View | Listen | |
| 8/7/2013 | Q2 2013 | ($0.40) | ($0.37) | $11.11 million | $13.90 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.38) | ($0.36) | $5.01 million | $6.40 million | View | Listen | |
| 2/25/2013 | Q4 2012 | ($0.36) | ($0.36) | $78.00 million | $0.07 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.32) | ($0.32) | $0.96 million | $0.85 million | View | N/A | |
| 8/2/2012 | | ($0.27) | ($0.31) | | | View | N/A | |
| 5/9/2012 | | ($0.23) | ($0.35) | | | View | N/A | |
| 2/28/2012 | | ($0.20) | ($0.38) | | | View | N/A | |
| 11/3/2011 | | $0.02 | $0.10 | | | View | N/A | |
| 8/2/2011 | | ($0.16) | ($0.36) | | | View | N/A | |
| 5/5/2011 | | ($0.13) | ($0.29) | | | View | N/A | |
| 2/17/2011 | | ($0.14) | ($0.25) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)2017 EPS Consensus Estimate: ($1.06)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.24) | ($0.21) | ($0.23) |
| Q2 2017 | 2 | ($0.23) | ($0.21) | ($0.22) |
| Q3 2017 | 2 | ($0.22) | ($0.22) | ($0.22) |
| Q4 2017 | 2 | ($0.57) | ($0.21) | ($0.39) |
(Data provided by Zacks Investment Research)
Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ariad Pharmaceuticals (NASDAQ:ARIA)Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 86.97%
Insider Trades by Quarter for Ariad Pharmaceuticals (NASDAQ:ARIA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/9/2017 | Daniel M Bollag | VP | Sell | 32,000 | $23.78 | $760,960.00 | |
| 10/24/2016 | Timothy P Clackson | Insider | Sell | 19,638 | $9.56 | $187,739.28 | |
| 10/3/2016 | Daniel M Bollag | VP | Sell | 47,384 | $13.46 | $637,788.64 | |
| 9/28/2016 | Timothy P Clackson | Insider | Sell | 8,750 | $13.98 | $122,325.00 | |
| 9/22/2016 | Timothy P Clackson | Insider | Sell | 20,000 | $13.43 | $268,600.00 | |
| 9/15/2016 | Timothy P Clackson | Insider | Sell | 59,369 | $11.73 | $696,398.37 | |
| 8/22/2016 | Timothy P Clackson | Insider | Sell | 19,436 | $10.47 | $203,494.92 | |
| 8/12/2016 | Timothy P Clackson | Insider | Sell | 25,000 | $10.50 | $262,500.00 | |
| 7/22/2016 | Timothy P Clackson | Insider | Sell | 18,286 | $8.11 | $148,299.46 | |
| 6/28/2016 | Hugh M Cole | SVP | Sell | 6,012 | $7.05 | $42,384.60 | |
| 6/22/2016 | Timothy P Clackson | Insider | Sell | 23,999 | $7.28 | $174,712.72 | |
| 6/15/2016 | Athanese Lavidas | Director | Sell | 76,250 | $8.21 | $626,012.50 | |
| 6/14/2016 | Massimo Radaelli | Director | Sell | 108,569 | $8.25 | $895,694.25 | |
| 5/23/2016 | Timothy P Clackson | Insider | Sell | 17,762 | $8.08 | $143,516.96 | |
| 5/12/2016 | Paris Panayiotopoulos | CEO | Buy | 26,990 | $7.41 | $199,995.90 | |
| 5/2/2016 | Timothy P Clackson | Insider | Sell | 11,700 | $7.13 | $83,421.00 | |
| 4/22/2016 | Timothy P Clackson | Insider | Sell | 21,409 | $7.37 | $157,784.33 | |
| 3/22/2016 | Timothy P Clackson | Insider | Sell | 23,834 | $6.58 | $156,827.72 | |
| 3/21/2016 | David L Berstein | SVP | Sell | 2,375 | $6.47 | $15,366.25 | |
| 3/21/2016 | Edward M Fitzgerald | VP | Sell | 5,417 | $6.47 | $35,047.99 | |
| 3/21/2016 | Frank Haluska | CMO | Sell | 3,575 | $6.47 | $23,130.25 | |
| 3/19/2016 | Maria E Cantor | SVP | Sell | 3,575 | $6.46 | $23,094.50 | |
| 3/19/2016 | Martin J Duvall | EVP | Sell | 4,000 | $6.47 | $25,880.00 | |
| 3/19/2016 | Timothy P Clackson | Insider | Sell | 5,417 | $6.47 | $35,047.99 | |
| 3/3/2016 | Daniel M Bollag | VP | Sell | 9,625 | $6.11 | $58,808.75 | |
| 3/3/2016 | Frank Haluska | CMO | Sell | 10,588 | $6.11 | $64,692.68 | |
| 3/3/2016 | Timothy P Clackson | Insider | Sell | 34,672 | $6.03 | $209,072.16 | |
| 2/1/2016 | Edward M. Fitzgerald | CFO | Sell | 14,667 | $4.81 | $70,548.27 | |
| 2/1/2016 | Maria E. Cantor | SVP | Sell | 16,133 | $4.82 | $77,761.06 | |
| 2/1/2016 | Paris Panayiotopoulos | CEO | Buy | 61,099 | $4.91 | $299,996.09 | |
| 9/28/2015 | David L. Berstein | SVP | Sell | 5,000 | $6.46 | $32,300.00 | |
| 9/28/2015 | Frank Haluska | CMO | Sell | 5,500 | $6.46 | $35,530.00 | |
| 9/28/2015 | Timothy P. Clackson | insider | Sell | 8,750 | $6.46 | $56,525.00 | |
| 9/1/2015 | Maria E Cantor | SVP | Sell | 2,696 | $9.11 | $24,560.56 | |
| 8/28/2015 | Edward M Fitzgerald | CFO | Sell | 32,858 | $10.00 | $328,580.00 | |
| 8/28/2015 | Maria E Cantor | SVP | Sell | 1,268 | $10.00 | $12,680.00 | |
| 7/16/2015 | David L Berstein | SVP | Sell | 4,000 | $8.54 | $34,160.00 | |
| 7/16/2015 | Edward M Fitzgerald | CFO | Sell | 7,000 | $8.54 | $59,780.00 | |
| 7/16/2015 | Frank Haluska | CMO | Sell | 4,400 | $8.54 | $37,576.00 | |
| 7/16/2015 | Martin J Duvall | EVP | Sell | 1,400 | $8.54 | $11,956.00 | |
| 5/1/2015 | Edward M Fitzgerald | CFO | Sell | 60,000 | $8.80 | $528,000.00 | |
| 4/23/2015 | Timothy P Clackson | Insider | Sell | 123,766 | $9.50 | $1,175,777.00 | |
| 3/23/2015 | Daniel M Bollag | VP | Sell | 7,000 | $8.72 | $61,040.00 | |
| 3/23/2015 | Edward M Fitzgerald | CFO | Sell | 9,584 | $8.72 | $83,572.48 | |
| 3/23/2015 | Frank Haluska | CMO | Sell | 6,875 | $8.71 | $59,881.25 | |
| 3/23/2015 | Maria E Cantor | SVP | Sell | 16,954 | $8.86 | $150,212.44 | |
| 3/23/2015 | Martin J Duvall | EVP | Sell | 4,834 | $8.80 | $42,539.20 | |
| 3/23/2015 | Timothy P Clackson | Insider | Sell | 32,741 | $8.88 | $290,740.08 | |
| 2/12/2015 | Harvey J M D Berger | CEO | Buy | 25,000 | $6.83 | $170,750.00 | |
| 2/2/2015 | Frank Haluska | CMO | Sell | 16,134 | $6.33 | $102,128.22 | |
| 1/23/2015 | Harvey J M D Berger | CEO | Buy | 25,000 | $6.17 | $154,250.00 | |
| 1/14/2015 | Sarah J Schlesinger | Director | Buy | 2,600 | $6.61 | $17,186.00 | |
| 12/18/2014 | Harvey J M D Berger | CEO | Buy | 25,000 | $6.35 | $158,750.00 | |
| 12/17/2014 | Sarah J Schlesinger | Director | Buy | 2,600 | $6.09 | $15,834.00 | |
| 11/24/2014 | Maria E Cantor | SVP | Sell | 1,749 | $7.00 | $12,243.00 | |
| 11/20/2014 | Harvey J M D Berger | CEO | Buy | 25,000 | $6.15 | $153,750.00 | |
| 11/12/2014 | Sarah J Schlesinger | Director | Buy | 2,600 | $6.26 | $16,276.00 | |
| 9/10/2014 | Sarah J Schlesinger | Director | Buy | 5,200 | $5.73 | $29,796.00 | |
| 8/15/2014 | Alexander J Denner | Director | Buy | 850,000 | $5.83 | $4,955,500.00 | |
| 4/2/2014 | Daniel Bollag | VP | Sell | 2,400 | $8.22 | $19,728.00 | |
| 4/2/2014 | Frank Haluska | CMO | Sell | 3,400 | $8.21 | $27,914.00 | |
| 4/2/2014 | Maria Cantor | SVP | Sell | 4,250 | $8.21 | $34,892.50 | |
| 4/2/2014 | Timothy Clackson | Insider | Sell | 6,500 | $8.21 | $53,365.00 | |
| 3/21/2014 | Daniel Bollag | VP | Sell | 2,400 | $7.89 | $18,936.00 | |
| 3/21/2014 | David Berstein | SVP | Sell | 1,600 | $7.89 | $12,624.00 | |
| 3/21/2014 | Timothy Clackson | Insider | Sell | 6,667 | $7.89 | $52,602.63 | |
| 12/19/2013 | David Berstein | VP | Sell | 4,500 | $5.14 | $23,130.00 | |
| 12/19/2013 | Frank Haluska | CMO | Sell | 5,100 | $5.14 | $26,214.00 | |
| 12/19/2013 | Maria Cantor | SVP | Sell | 6,375 | $5.14 | $32,767.50 | |
| 12/19/2013 | Timothy Clackson | Insider | Sell | 9,750 | $5.14 | $50,115.00 | |
| 9/6/2013 | Timothy P Clackson | Insider | Sell | 8,449 | $22.00 | $185,878.00 | |
| 8/14/2013 | Harvey Berger | CEO | Sell | 118,759 | $18.34 | $2,178,040.06 | |
| 7/18/2013 | Frank Haluska | CMO | Sell | 6,400 | $19.79 | $126,656.00 | |
| 7/18/2013 | Maria E Cantor | SVP | Sell | 8,000 | $19.79 | $158,320.00 | |
| 7/18/2013 | Timothy P Clackson | Insider | Sell | 14,000 | $19.79 | $277,060.00 | |
| 7/17/2013 | Harvey J M D Berger | CEO | Sell | 199,400 | $19.84 | $3,956,096.00 | |
| 6/19/2013 | Harvey J M D Berger | CEO | Sell | 11,200 | $18.00 | $201,600.00 | |
| 5/15/2013 | Harvey J M D Berger | CEO | Sell | 92,498 | $18.10 | $1,674,213.80 | |
| 3/26/2013 | Edward M Fitzgerald | CFO | Sell | 12,933 | $18.75 | $242,493.75 | |
| 3/25/2013 | Daniel M Bollag | VP | Sell | 12,933 | $18.87 | $244,045.71 | |
| 3/25/2013 | Frank Haluska | CMO | Sell | 5,333 | $18.88 | $100,687.04 | |
| 3/25/2013 | Pierre F Dodion | SVP | Sell | 8,133 | $18.87 | $153,469.71 | |
| 3/25/2013 | Timothy P Clackson | Insider | Sell | 19,167 | $18.87 | $361,681.29 | |
| 3/13/2013 | Harvey J M D Berger | CEO | Sell | 105,400 | $22.05 | $2,324,070.00 | |
| 12/21/2012 | Athanese Lavidas | Director | Sell | 10,500 | $20.31 | $213,255.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ariad Pharmaceuticals (NASDAQ:ARIA)
Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
| Source: |
|
| Date | Headline |
|---|
 | Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations
www.bizjournals.com - October 10 at 5:24 PM |
| Shire officially inks sublease for former Ariad site in Cambridge - Boston Business Journal
www.bizjournals.com - October 5 at 6:50 PM |
 | Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal ... - Business Wire (press release)
www.businesswire.com - September 28 at 8:00 AM |
| Incyte seeking $666.6 million from stock sale
www.bizjournals.com - September 12 at 9:20 PM |
 | Why Acadia Pharma Could be Worth $10 Billion | Investopedia - Investopedia
www.investopedia.com - September 11 at 3:53 PM |
 | Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - PR Newswire (press release)
www.prnewswire.com - September 9 at 3:50 PM |
| Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors - PR Newswire (press release)
www.prnewswire.com - September 9 at 3:50 PM |
 | Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors
finance.yahoo.com - September 7 at 4:01 PM |
 | Takeda Pharmaceutical Prescribes Stability After Rough Start
www.msn.com - September 5 at 10:42 PM |
| Takeda CEO Prescribes Stability After Rough Start
www.msn.com - September 5 at 5:39 PM |
 | Judge OKs ex-Ariad employee's SEC pact after questioning fairness
www.reuters.com - August 16 at 9:28 PM |
| Compugen Welcomes Paul Sekhri as its New Chairman of the Board - PR Newswire (press release)
www.prnewswire.com - August 3 at 2:54 AM |
| Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs
www.businesswire.com - August 1 at 4:57 PM |
 | Japanese drugmaker Takeda posts stronger profit as US sales jump - Nasdaq
www.nasdaq.com - July 29 at 3:45 PM |
| UPDATE 1-Japanese drugmaker Takeda posts stronger profit as US sales jump - Reuters
www.reuters.com - July 28 at 5:10 PM |
 | Ex-Ariad employee's husband charged in US with insider trading - Business Insider
www.businessinsider.com - July 22 at 3:56 PM |
| Ex-Ariad employee's husband charged with insider trading
www.reuters.com - July 22 at 3:34 AM |
| Ex-Ariad employee's husband charged with insider trading - Reuters - Reuters
www.reuters.com - July 21 at 3:30 AM |
| Ex-Ariad employee's husband charged in U.S. with insider trading - Reuters
www.reuters.com - July 20 at 5:26 PM |
| What Sprycel Could Mean for Bristol-Myers Squibb
finance.yahoo.com - July 10 at 4:02 PM |
 | Merrimack: A Special Situation With A Compelling Risk/Reward
seekingalpha.com - July 6 at 5:23 PM |
| SEC charges two former Ariad Pharmaceuticals executives with ... - Boston Business Journal
www.bizjournals.com - June 29 at 5:06 PM |
 | SEC charges three with insider trading in cancer drug company - MarketWatch
www.marketwatch.com - June 27 at 3:45 PM |
| Mersana Therapeutics Kicks Off A Major IPO Week
seekingalpha.com - June 26 at 9:14 PM |
| Bellevue Group AG Buys Align Technology Inc, Anthem Inc, Walgreens Boots Alliance Inc, Sells ...
www.nasdaq.com - May 12 at 4:10 PM |
 | Alnylam Pharma (ALNY) Names Manmeet S. Soni as CFO - StreetInsider.com
www.streetinsider.com - May 9 at 9:09 AM |
| Takeda Announces Publication of ALUNBRIG™ (brigatinib) Pivotal Phase 2 ALTA Clinical Trial Data in Journal of Clinical Oncology
www.businesswire.com - May 8 at 10:49 AM |
| Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda
www.nasdaq.com - April 30 at 2:27 AM |
| General American Investors Co Inc Buys Ensco PLC, Johnson Controls International PLC, Liberty ...
www.nasdaq.com - April 29 at 4:14 PM |
| Evercore Partners' (EVR) CEO Ralph Schlosstein on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - April 26 at 3:53 PM |
 | Ariad Pharmaceuticals (ARIA) Flat with Quarterly Loss Projected
www.baystreet.ca - April 12 at 11:48 AM |
| Tocagen IPO Could Garner Significant Investor Attention
seekingalpha.com - April 11 at 8:05 AM |
 | 7-Eleven to Buy Sunoco Shops in Record $3.3 Billion U.S. Bet
www.bloomberg.com - April 7 at 3:38 PM |
 | After Soaring to $150, Can Incyte Stir Up More Upside?
www.thestreet.com - March 15 at 3:49 PM |
| Trump???s Immigration Plans an Overhang on Biotech ETFs?
www.nasdaq.com - March 2 at 3:51 PM |
| BRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals - Reuters
www.reuters.com - February 18 at 3:34 PM |
| BRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals
www.reuters.com - February 17 at 6:32 PM |
| Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US
www.prnewswire.com - February 16 at 8:41 PM |
| Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US
www.prnewswire.com - February 16 at 8:41 PM |
| Takeda Announces Completion of Acquisition of ARIAD Pharmaceuticals (ARIA)
www.streetinsider.com - February 16 at 8:41 PM |
| ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM |
| ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM |
| ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o
biz.yahoo.com - February 16 at 8:41 PM |
| Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.
au.finance.yahoo.com - February 16 at 3:40 PM |
| ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
us.rd.yahoo.com - February 8 at 8:53 PM |
| Ariad Submits Brigatinib Marketing Application (ARIA)
www.investopedia.com - February 7 at 1:44 AM |
 | ARIAD Pharma Reports Submission Of MAA For Brigatinib To EMA
www.rttnews.com - February 7 at 1:44 AM |
 | 7:35 am Ariad Pharm submits a MMA for its ALK inhbiter, brigatinib, to the EMA
us.rd.yahoo.com - February 7 at 1:44 AM |
| ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
us.rd.yahoo.com - February 7 at 1:44 AM |
Ariad Pharmaceuticals (ARIA) Chart for Tuesday, October, 17, 2017
